Abstracts tagged "prevention"

Abstract Number: 1596 • ACR Convergence 2022
The Role of Coronary Calcium Screening in Patients with Lupus Who Appear to Be at Low Cardiovascular Risk
Sarah Stoots¹, Joshua Baker¹ and Joan Von Feldt², ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Wilmington, DE
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) are at elevated cardiovascular risk. However, common risk calculators such as the atherosclerotic cardiovascular disease (ASCVD) risk estimator…
Abstract Number: 0727 • ACR Convergence 2022
Primary Prevention of Fractures in Osteoporotic Patients in a Southern California Academic Health System
Eugene Looi¹, Gergana Mishkova¹ and Christina Downey², ¹Loma Linda University, Loma Linda, CA, ²Loma Linda University Medical Center, Redlands, CA
Background/Purpose: Osteoporosis (OSP) is common, carries high morbidity, significant cost and remains underrecognized and undertreated by health care providers (1). At a university-based academic health…
Abstract Number: 1603 • ACR Convergence 2022
Intervention with Methotrexate in Arthralgia at Risk for Rheumatoid Arthritis to Reduce the Development of Persistent Arthritis and Its Disease Burden (TREAT EARLIER): A Double-blind, Randomized, Placebo-controlled Trial
Doortje Krijbolder¹, Marloes Verstappen¹, Bastiaan van Dijk², Yousra Dakkak¹, Aleid Boer¹, Yune-Jung Park¹, Marianne E. de Witt-Luth³, Karen Visser⁴, Marc Kok⁵, Esmeralda T.H. Molenaar⁶, Pascal de Jong⁷, Stephan Böhringer⁸, Tom Huizinga¹, CF Allaart¹, Ellis Niemantsverdriet⁹ and Annette van der Helm-van Mil¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre (LUMC), Leiden, Netherlands, ³Reinier de Graaf Ziekenhuis, Delft, Netherlands, ⁴Haga Ziekenhuis, Amsterdam, Netherlands, ⁵Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam, Netherlands, ⁶Groene Hart Ziekenhuis, Gouda, Netherlands, ⁷ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁸Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Leiden, Netherlands, ⁹LUMC, Leiden, Netherlands, ¹⁰Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is the most common autoimmune disease and requires long term treatment to suppress inflammation. Currently, treatment is started when arthritis is…
Abstract Number: 0781 • ACR Convergence 2022
Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose
Daniel Magliulo¹, Vasileios Kyttaris¹ and Emily Rose², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, West Roxbury, MA
Background/Purpose: Rituximab (RTX) is a very effective treatment for autoimmune rheumatic diseases (AIRD). However, treatment increases risk of infections and impairs responses to vaccines. Prior…
Abstract Number: 1604 • ACR Convergence 2022
Hydroxychloroquine Does Not Prevent the Future Development of Rheumatoid Arthritis in a Population with Baseline High Levels of Antibodies to Citrullinated Protein Antigens and Absence of Inflammatory Arthritis: Interim Analysis of the StopRA Trial
Kevin D Deane¹, Christopher Striebich², Marie Feser³, Kristen Demoruelle³, LauraKay Moss⁴, Elizabeth Bemis³, Ashley Frazer-Abel⁴, Chelsie Fleischer⁴, Jeffrey Sparks⁵, Elizabeth Solow⁶, Judith James⁷, Joel Guthridge⁷, John Davis⁸, Jonathan Graf⁹, Jonathan Kay¹⁰, Maria Danila¹¹, S. Louis Bridges, Jr.¹², Lindsy Forbess¹³, James O'Dell¹⁴, Maureen McMahon¹⁵, Jennifer Grossman¹⁵, Diane Horowitz¹⁶, Athan Tiliakos¹⁷, Elena Schiopu¹⁸, David Fox¹⁹, Jeffrey Carlin²⁰, Cristina Arriens⁷, Vivian Bykerk¹², Reem Jan²¹, Mathilde Pioro²², M. Elaine Husni²³, Ana Fernandez-Pokorny²⁴, Sarah Walker²⁵, Susan Booher²⁶, Melissa Greenleaf²⁷, Margie Byron²⁵, Lynette Keyes-Elstein²⁵, Ellen Goldmuntz²⁸ and V. Michael Holers²⁹, ¹University of Colorado Denver Anschutz Medical Campus, Denver, CO, ²University of Colorado, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Colorado Denver, Denver, CO, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶UT Southwestern Medical Center, Dallas, TX, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Mayo Clinic, Rochester, MN, ⁹Ucsf, San Francisco, CA, ¹⁰Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, ¹¹University of Alabama at Birmingham, Birmingham, AL, ¹²Hospital for Special Surgery, New York, NY, ¹³Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁴University of Nebraska Medical Center, Omaha, NE, ¹⁵University of California Los Angeles, Los Angeles, CA, ¹⁶Northwell Health, Jericho, NY, ¹⁷Emory University, Roswell, GA, ¹⁸Michigan Medicine, Ann Arbor, MI, ¹⁹University of Michigan, Ann Arbor, MI, ²⁰Virginia Mason Medical Center, Seattle, WA, ²¹University of Chicago, Chicago, IL, ²²University of Washington, Seattle, WA, ²³Cleveland Clinic, Cleveland, OH, ²⁴Essentia Health, Duluth, MN, ²⁵Rho, Chapel Hill, NC, ²⁶NIH NIAID, Bethesda, MD, ²⁷NIH, Rock Hill, SC, ²⁸NIAID/ NIH, Washington, DC, ²⁹University of Colorado, Denver, CO
Background/Purpose: The Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (StopRA) (ClinicalTrials.gov NCT02603146) is a randomized, double-masked, placebo-controlled, multi-center (20 sites) clinical trial evaluating…
Abstract Number: 0800 • ACR Convergence 2022
Antibody Response to Shingrix Vaccination in Patients with Rheumatoid Arthritis, Seronegative Spondyloarthropathy and Systemic Lupus Erythematosus on Immunosuppressive Medications
Alina Kifayat¹, amy Wasserman², Kirk Sperber¹, Deana Nes³, Paul Arnaboldi⁴ and Julia Ash⁵, ¹New York Medical College at Westchester Medical Center, Valhalla, NY, ²New York Medical College at Westchester Medical Center, Armonk, NY, ³Bergen Medical Associates, Ridgewood, NJ, ⁴New York Medical College, Valhalla, NY, ⁵New York Medical College at Westchester Medical Center, Dobbs Ferry, NY
Background/Purpose: In patients with rheumatic diseases herpes zoster (HZ) has been identified as one of the most common infections associated with immunosuppression. Shingrix is a…
Abstract Number: 1612 • ACR Convergence 2022
Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of a New Scoring System for Psoriatic Arthritis Risk
Lihi Eder¹, Ker-Ai Lee², Vinod Chandran³, Jessica Widdifield⁴, Aaron Drucker⁴, Christopher Ritchlin⁵, Cheryl F Rosen⁴, Richard Cook² and Dafna Gladman⁶, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: A simple, scalable tool that identifies psoriasis patients at high risk for developing PsA could improve early detection and facilitate early intervention. Our overall…
Abstract Number: 0896 • ACR Convergence 2022
Screening of Lipids in Patients with Rheumatoid Arthritis: Academic Rheumatology Practice Quality Improvement Analysis
Sukhraj Singh¹ and Gurjit S. Kaeley², ¹University of Florida-Jacksonville, Jacksonville, FL, ²UF COM-J, Ponte Vedra Beach, FL
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have 50% increased risk of cardiovascular disease (CVD) mortality compared with the general population. The American College of Cardiology/American…
Abstract Number: 1756 • ACR Convergence 2022
Adverse Events in Patients with Inflammatory Joint Diseases: Results from the EULAR Coronavirus Vaccine (COVAX) Physician-reported Registry
Ana Lúcia Martins Fernandes¹, Jose A Gomez-Puerta², Juan Camilo Sarmiento-Monroy², Saskia Lawson-Tovey³, Kimme Hyrich⁴, Laure Gossec⁵, Loreto Carmona⁶, Anja Strangfeld⁷, Elsa Mateus⁸, Ana Maria Rodrigues⁹, Eric Hachulla¹⁰, Marta Mosca¹¹, Patrick Durez¹², Bernd Raffeiner¹³, Nicolas Roux¹⁴, Viellard Eric¹⁵, Olivier Brocq¹⁶, Julija Zepa¹⁷, Inita Bulina¹⁸, Eva Strakova¹⁹, Vanda Mlynarikova²⁰, Emoke Šteňová²¹, Martin Soubrier²², Xavier Mariette²³ and Pedro Machado²⁴, ¹Centro Hospitalar Universitário do Algarve, Faro, Portugal, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK AND National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴The University of Manchester, Manchester, United Kingdom, ⁵Sorbonne Université, Paris, France, ⁶Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁷Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁸EULAR, Lisboa, Portugal, ⁹Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal, ¹⁰University of Lille, LILLE, France, ¹¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹²Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ¹³Department of Rheumatology, Central Hospital of Bolzano, Bolzano, Italy, ¹⁴Service de Rhumatologie, Hôpital Robert Schuman, Metz, France, ¹⁵Private practice, St. Malo, France, ¹⁶Rheumatology- CH Princesse Grace, Monaco, Monaco, ¹⁷Riga Stradins University, Latvia, Pauls Stradins Clinical University Hospital, Centre of Rheumatology, Riga, Latvia, Riga, Latvia, ¹⁸Center of Rheumatology, Paul Stradins Clinical University hospital, Riga, Latvia, Riga, Latvia, ¹⁹Department of Internal Medicine, Faculty Hospital Prešov, Presov, Slovakia, ²⁰National Institute of Rheumatic Diseases, Piešťany, Slovakia, ²¹University Hospital, Bratislava, Slovakia, ²²Gabriel-Montpied Hospital, Clermont-Ferrand, France, ²³Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ²⁴University College London, London, United Kingdom
Background/Purpose: Patients with inflammatory/autoimmune rheumatic and musculoskeletal diseases (I-RMDs) were excluded from SARS-CoV-2 vaccination development programs. Therefore, concerns regarding the safety and effectiveness of SARS-CoV-2…
Abstract Number: 0911 • ACR Convergence 2022
Peer Coach Intervention to Improve Primary Cardiovascular Disease Screening for Patients with Rheumatoid Arthritis
Iris Navarro-Millan¹, Mackenzie Brown², Yuliana Domínguez Páez³, Geyanne Lui⁴, Joan Weiner¹, Shelley fritz¹, Tien Sydnor-Campbell⁵, Aberdeen Allen⁶, Assem Jabri¹, Shilpa Venkatachalam⁷, Kelly Gavigan⁸, William Benjamin Nowell⁹, Jeffrey Curtis¹⁰, Liana Fraenkel¹¹ and Monika Safford¹, ¹Weill Cornell Medicine, New York, NY, ²Weill Cornell Medicine, Brooklyn, NY, ³Weill Cornell Medicine, Bronx, NY, ⁴Albert Einstein College of Medicine, New York, NY, ⁵Weill Cornell Medicine, Philedelphia, ⁶Weill Cornell Medicine, Parlin, ⁷Global Healthy Living Foundation, New York, NY, ⁸Global Healthy Living Foundation, Upper Nyack, NY, ⁹Global Healthy Living Foundation, Nyack, NY, ¹⁰University of Alabama at Birmingham, Hoover, AL, ¹¹Berkshire Medical Center, Lenox, MA
Background/Purpose: Only 37% of patients with rheumatoid arthritis (RA) receive screening for cardiovascular disease (CVD) despite their high risk. To improve CVD prevention, we designed…
Abstract Number: 1815 • ACR Convergence 2022
Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease
Gary Ho¹, Michael Toprover², Daria Crittenden³, binita Shah⁴ and Michael Pillinger⁵, ¹New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, ²Division of Rheumatology, New York University Grossman School of Medicine and Rheumatology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY, ³CymaBay Therapeutics, New York University Grossman School of Medicine, Newark, CA, ⁴New York University Grossman School of Medicine, VA New York Harbor Health Care System, New York, NY, ⁵NYU Grossman School of Medicine, New York, NY
Background/Purpose: Patients with gout are more likely than those without to have traditional risk factors for cardiovascular (CV) disease. Furthermore, the chronic, low-level inflammation experienced…
Abstract Number: 1725 • ACR Convergence 2021
Higher Prevalence of Aspirin Use with a Specific Educational Tool in SLE Pregnancies: Preliminary Results
Joo Young (Esther) Lee¹, Arielle Mendel², Isabelle Malhamé², Sasha Bernatsky¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Pregnant women with SLE are at substantial risk of preeclampsia. Best international practice guidelines recommend aspirin (ASA) in this population, as it reduces preeclampsia…
Abstract Number: 1896 • ACR Convergence 2021
Initial Results from the Implementation of a National Hydroxychloroquine Safe Prescribing Dashboard Within the Veterans Health Administration
Anna Montgomery¹, Gary Tarasovsky², Iziegbe Ehiorobo³, Mary Whooley², Jennifer Barton⁴, Khushboo Sheth⁵, Kimberly Reiter⁶, Meredith Keller⁷, Lorinda Chung⁸, Lori Bennett⁹, Jo Dana², Elizabeth Wahl¹⁰ and Gabriela Schmajuk³, ¹Department of Veterans Affairs, Tiburon, CA, ²San Francisco VA Healthcare System, San Francisco, CA, ³University of California San Francisco, San Francisco, CA, ⁴Portland VA Healthcare System, Portland, OR, ⁵Stanford University/VA Palo Alto, Atherton, CA, ⁶Raymond G Murphy VA Medical Center, Albuquerque, NM, ⁷New Mexico VA Health Care System, Albuquerque, NM, ⁸Stanford University, Palo Alto, CA, ⁹Charleston VAHCS, Charleston, SC, ¹⁰VA Puget Sound Health Care System, Seattle, WA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication for patients with lupus erythematosus, rheumatoid arthritis, and other autoimmune conditions. However, HCQ daily doses of ≥…
Abstract Number: 0091 • ACR Convergence 2021
Vaccination of Patients with Chronic Inflammatory Rheumatic Diseases: An Analysis of Barriers and Facilitators in a Prospective Cohort
Ioana Andreica, Iulia Roman, Xenofon Baraliakos, Juergen Braun and Uta Kiltz, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Patients (pts.) with chronic inflammatory rheumatic diseases (CIRD) are often not adequately protected against infectious diseases. As shown in an earlier study, less than…
Abstract Number: 0100 • ACR Convergence 2021
Safety of COVID-19 Vaccines After First Vaccination in Patients with Rheumatic Diseases in a Patient Reported Survey
Rebecca Hasseli¹, Bimba Franziska Hoyer², Hanns-Martin Lorenz³, Alexander Pfeil⁴, Jutta Richter⁵, Anne Regierer⁶, Tim Schmeiser⁷, Anja Strangfeld⁸, Reinhard Voll⁹, Andreas Krause¹⁰, Hendrik Schulze-Koops¹¹, Ulf Müller-Ladner¹² and Christof Specker¹³, ¹Justus-Liebig-University Giessen, Bad Nauheim, Germany, ²Universittsklinikum Schleswig-Holstein, Kiel, Germany, ³University Hospital Heidelberg Germany, Heidelberg, Germany, ⁴Friedrich Schiller University Jena, Jena, Germany, ⁵Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, ⁶German Rheumatism Research Center, Berlin, Germany, ⁷Private Practice, Cologne, Germany, ⁸Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁹Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ¹⁰Immanuel Hospital, Berlin, Germany, ¹¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹²JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, ¹³Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany
Background/Purpose: Among patients with rheumatic and musculoskeletal diseases (RMDs) and their treating physicians, concerns prevail about the effectiveness and safety of vaccination against COVID-19, especially…

« Previous Page
1
…
8
9
10
11
12
…
15
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].